Clinical Trial Update: Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia [Phase 2]

View source ↗

Summary

Phase 2 safety, tolerability, and pharmacokinetic study of ISIS ApoC-III Rx in hypertriglyceridemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertriglyceridemia

Drugs mentioned

• ISIS ApoC-III Rx (is ApoC-III targeted antisense oligonucleotide (ISIS ApoC-III Rx))

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Hypertriglyceridemia | Phase 2 | Status: COMPLETED